Kato ET, et al. – Given that dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure (HHF) in a sample of patients with type 2 diabetes mellitus, researchers investigated the effect of baseline left ventricular ejection fraction (EF) on the clinical benefit of sodium-glucose cotransporter 2 inhibition. The study sample consisted of 17,160 patients, among whom 3.9% had heart failure (HF) with reduced EF (HFrEF), 7.7% had HF without known reduced EF, and 88.4% had no history of HF at baseline. Overall, in this first sodium-glucose cotransporter 2 inhibitor cardiovascular outcome trial to evaluate patients with type 2 diabetes mellitus stratified by EF, the investigators found that dapagliflozin treatment reduced HHF in patients with and without HFrEF and reduced cardiovascular and all-cause mortality in patients with HFrEF.